Company Overview - Beijing Baipusi Biotechnology Co., Ltd. (Baipusi) has submitted its listing application to the Hong Kong Stock Exchange, with CMB International as its sole sponsor [1] - Baipusi is a leading player in the biological reagent industry, particularly in the recombinant protein segment, ranking first among domestic suppliers in China and third globally by revenue in 2024 [1][3] - The company offers a comprehensive product portfolio that includes high-quality biological reagents and various technical services, supporting the entire value chain of biopharmaceutical companies from R&D to clinical applications [3][5] Financial Performance - For the fiscal year 2023, Baipusi reported revenues of approximately RMB 544 million, with projected revenues of RMB 645 million for 2024 and RMB 613 million for the nine months ending September 30, 2025 [6][10] - The gross profit for 2023 was around RMB 459 million, with a gross margin of 84.3%, and is expected to maintain a gross margin of approximately 82.2% in 2025 [8][10] - The company recorded a profit of approximately RMB 148 million for 2023, with a projected profit of RMB 132 million for the nine months ending September 30, 2025 [10][11] Market Overview - The global life sciences tools market reached USD 32.1 billion in 2020 and is projected to grow at a CAGR of 5.2% to USD 39.3 billion by 2024, further expanding to USD 61 billion by 2030 [12] - The biological reagent market, which includes products and services, was valued at USD 18.2 billion in 2020, with expectations to grow to USD 25.1 billion by 2024, and USD 35.6 billion by 2030 [14][16] - The recombinant protein market is anticipated to grow from USD 1 billion in 2020 to USD 3 billion by 2024, with a CAGR of 31.9%, and further to USD 7.8 billion by 2030 [18][19] Business Model - Baipusi operates on a "dual-engine" business model in China and the United States, allowing it to acquire advanced technological knowledge and efficient production capabilities [5] - The company serves a diverse clientele, including the top 20 global pharmaceutical companies and the top five life sciences service providers, with a 100% repurchase rate from its top clients [5][6] - Baipusi's production facilities in Beijing and Suzhou comply with international quality standards, including ISO certifications and GMP [6]

| 编纂 的[编纂]數目 :: | [编纂]股H股(視乎[编纂]行使與否而定) | | --- | --- | | [编纂]數目 : | [编纂]股H股(可予重新分配) | | [编纂]數目 : | [編纂]股H股(可予重新分配及視乎[編纂]行使與否 | | | 定) | | 最高[編纂] : 每股H股[编纂]港元,另加1.0%經紀佣金、0.0027% | | | | 證監會交易徵費、0.00565%的聯交所交易費以 | | | 及0.00015%的會財局交易徵費(須於申請時以港 | | | 元繳足,可予退還) | | 面值 | 每股H股人民幣1.00元 | | 股份代號 : [·] | | 智通财经APP获悉，据港交所1月26日披露，北京百普赛斯生物科技股份有限公司(简称：百普赛斯， 301080.SZ)向港交所主板递交上市申请书，招商证券国际为其独家保荐人。招股书显示，百普赛斯是全 球生命科学工具及技术服务提供商，致力于赋能生物制药公司覆盖研发、生产及临床应用的全价值链。 根据弗若斯特沙利文的资料，在全球重组蛋白市场中，按2024年收入计，公司在所有中国本土供应商中 排名第一，在全球所有供应商中排名第三。 ...

智通财经APP获悉，据港交所1月26日披露，北京百普赛斯生物科技股份有限公司(简称：百普赛斯， 301080.SZ)向港交所主板递交上市申请书，招商证券国际为其独家保荐人。招股书显示，百普赛斯是全 球生命科学工具及技术服务提供商，致力于赋能生物制药公司覆盖研发、生产及临床应用的全价值链。 根据弗若斯特沙利文的资料，在全球重组蛋白市场中，按2024年收入计，公司在所有中国本土供应商中 排名第一，在全球所有供应商中排名第三。 | ■纂]的[编纂]數目 | .. | [编纂]股H股(視乎[编纂]行使與否而定) | | --- | --- | --- | | [编纂]數目 | ። | [编纂]股H股(可予重新分配) | | [编纂 數目 | .. | [编纂]股H股(可予重新分配及視乎[编纂]行使與否 | | | | 定) | | 成尚[编纂] | | : 每股H股[編纂]港元,另加1.0%經紀佣金、0.0027% | | | | 證監會交易徵費、0.00565%的聯交所交易費以 | | | | 及0.00015%的會財局交易徵費(須於申請時以消 | | | | 元繳足,可予退還) | | 面值 | = | 每股H股 ...

据港交所1月26日披露，北京百普赛斯（301080）生物科技股份有限公司(简称：百普赛斯，301080.SZ) 向港交所主板递交上市申请书，招商证券国际为其独家保荐人。招股书显示，百普赛斯是全球生命科学 工具及技术服务提供商，致力于赋能生物制药公司覆盖研发、生产及临床应用的全价值链。根据弗若斯 特沙利文的资料，在全球重组蛋白市场中，按2024年收入计，公司在所有中国本土供应商中排名第一， 在全球所有供应商中排名第三。 | ■纂的[编纂]數目 | | : [編纂]股H股(視乎[編纂]行使與否而定) | | --- | --- | --- | | [编纂]數目 | .. | [编纂]股H股(可予更新分配) | | [编纂]數目 | .. | [编纂]股H股(可予重新分配及視乎[编纂]行使與否 | | | | 定) | | 取尚编纂1 | .. | 每股H股[編纂]港元,另加1.0%經紀佣金、0.0027% | | | | 證監會交易徵費、0.00565%的聯交所交易費以 | | | | 及0.00015%的會財局交易徵費(須於申請時以港 | | | | 元繳足,可予退還) | | 面值 | .. 每股H股人民幣1 ...

格隆汇1月26日｜据港交所文件，北京百普赛斯生物科技股份有限公司向港交所提交上市申请书。 ...

据港交所文件：北京百普赛斯生物科技股份有限公司向港交所提交上市申请书。 ...

截至1月26日收盘，猴痘概念上涨3.13%，位居概念板块涨幅第8，板块内，50股上涨，凯普生物、迈克 生物、之江生物等20%涨停，达安基因、科华生物等涨停，万孚生物、智飞生物、百普赛斯等涨幅居 前，分别上涨16.23%、14.87%、12.58%。跌幅居前的有谱尼测试、富祥药业、合富中国等，分别下跌 9.72%、5.51%、5.32%。 资金面上看，今日猴痘概念板块获主力资金净流入15.26亿元，其中，46股获主力资金净流入，6股主力 资金净流入超亿元，净流入资金居首的是智飞生物，今日主力资金净流入2.61亿元，净流入资金居前的 还有众生药业、君实生物、达安基因等，主力资金分别净流入2.23亿元、1.69亿元、1.65亿元。 今日涨跌幅居前的概念板块 | 688575 | 亚辉龙 | 1.73 | 2.31 | 1476.63 | 7.35 | | --- | --- | --- | --- | --- | --- | | 300439 | 美康生 | 5.17 | 7.59 | 1457.59 | 6.07 | | | 物 | | | | | | 300482 | 万孚生 | 16.23 | 15.99 | ...

Core Viewpoint - The A-share market shows a slight decline with the Shanghai Composite Index at 4133.16 points, just above the five-day moving average, indicating mixed market sentiment [1]. Group 1: Market Overview - As of 13:59 today, the total trading volume of A-shares reached 27,509.71 billion yuan [1]. - The Shanghai Composite Index experienced a change of -0.07% [1]. Group 2: Stocks Exceeding Five-Day Moving Average - A total of 165 A-shares have surpassed the five-day moving average today [1]. - Notable stocks with significant deviation rates include: - Baipusais (301080) with a deviation rate of 11.09% and a price increase of 14.92% [2]. - Huisheng Biological (300871) with a deviation rate of 10.40% and a price increase of 20.01% [2]. - Sidike (300806) with a deviation rate of 10.20% and a price increase of 14.84% [2]. - Other stocks with smaller deviation rates include: - Qianwei Yangchu (300492) with a deviation rate of 8.33% [2]. - Yuedong Nianqing (301111) with a deviation rate of 7.82% [2]. - Heshun Oil (603353) with a deviation rate of 7.50% [2].

Group 1 - The A-share market saw a significant rise in biopharmaceutical stocks, with notable increases such as Kanglaweishi up over 20% and several others reaching the daily limit of 20% [1] - The outbreak of Nipah virus in West Bengal, India, has prompted a response from local authorities, with nearly a hundred individuals under home quarantine due to the high mortality rate of up to 75% and the absence of a vaccine [1][2] - The Thai Civil Aviation Authority has announced comprehensive screening for flights from West Bengal starting January 26 to prevent the virus from entering Thailand [1] Group 2 - Historical context indicates that Nipah virus outbreaks have previously occurred in Malaysia, Singapore, India, Bangladesh, and the Philippines, resulting in significant fatalities and the culling of millions of pigs [2] - The World Health Organization classifies Nipah virus as a deadly zoonotic virus primarily carried by fruit bats, with a transmission rate through contaminated food or direct human-to-human contact [2] - The incubation period for Nipah virus ranges from 4 to 14 days, with a maximum of 45 days, and there are currently no specific vaccines or effective treatments available [2] Group 3 - The stock performance of various biopharmaceutical companies shows substantial year-to-date gains, with Kanglaweishi at 45.10%, Maike Biological at 26.90%, and Kaipu Biological at 34.76% [3] - Other companies such as Zhijiang Biological and Jindike also reported significant increases, with year-to-date growth rates of 26.67% and 18.44% respectively [3] - The overall market trend indicates a strong investor interest in biopharmaceutical stocks amid the health crisis related to the Nipah virus outbreak [1][3]

Group 1 - The A-share market saw a significant rise in biopharmaceutical stocks, with Kang Le Wei Shi increasing by over 20% and several other companies reaching their daily limit up of 20% [1] - The outbreak of Nipah virus in West Bengal, India, has led to a human-to-human transmission risk, with a mortality rate as high as 75% and no vaccine currently available [1][2] - The Thai Civil Aviation Authority has announced comprehensive screening for flights from West Bengal, India, starting January 26, to prevent the virus from entering Thailand [1] Group 2 - Historical context shows that Nipah virus outbreaks previously occurred in Malaysia and Singapore from 1998 to 1999, resulting in over a hundred deaths and the culling of a million pigs [2] - The World Health Organization classifies Nipah virus as a deadly zoonotic virus primarily carried by fruit bats, with a transmission potential through contaminated food or direct human contact [2] - The incubation period for Nipah virus ranges from 4 to 14 days, with a maximum of 45 days before symptoms appear [2] Group 3 - Notable stock performances include: - Kang Le Wei Shi: 20.48% increase, market cap of 3.371 billion - Mai Ke Biological: 20.03% increase, market cap of 8.586 billion - Kai Pu Biological: 20.03% increase, market cap of 4.687 billion - Zhi Jiang Biological: 20.01% increase, market cap of 4.910 billion - Jin Di Ke: 13.72% increase, market cap of 2.952 billion [3] - Other companies with significant increases include Zhi Fei Biological (13.31%), Kang Xi Nuo (12.77%), and Bai Pu Sai Si (12.01%) [3]